Investor Sam Adarangi
Sahm Adrangi is the Chief Investment Officer of Kerrisdale Capital Management, a limited liability capital in New York. The company was founded in 2009 and deals in investment management with a specialty in long-term value investment and unique situations. The company shares its investment ideas with the general investment community through its website. Sahm Adrangi has a bachelor of arts in economics from Yale University.
Before founding Kerrisdale, Sahm Adrangi worked at Longacre Fund Management as an investment analyst. He was responsible for conducting investment research and analysis for the company’s credit and equity funds. Before Longacre, Sahm Adrangi worked at Chanin Capital Partners where he advised creditors in out of court restructuring. He represented creditors of distressed and bankrupt companies. Before Chanin Capital Partners, Sahm Adrangi worked at Deutsche Bank where he structured non-investment bank debt and bonds with high yields.
Recently, Kerrisdale Capital Management issued a negative report on QuinStreet, an internet marketing company. The stock price of QuinStreet has multiplied making investors happy that the company is moving in the right direction. QuinStreet make money when clients click on links and fill forms on its websites. Kerrisdale noted that recent growth in revenue by QuinStreet is from a single client. The company is based on a flawed structure and model, and its sustainability and quality cannot be foreseen risking investors’ money.
In April 2018, Kerrisdale Capital gave a short report on St. Joe Company, a real estate company that hopes to develop a sizeable desolate land in Panama City Beach into an attractive residential and business hub. The company is currently valued at $1 billion, and Kerrisdale Capital is convinced that no form of development can transform the remaining swampy desolate areas to match the current value of the company. This valuation assumes that St. Joe sells 2700 residential regions and 400,000 square feet of commercial space. In reality, however, little is being done in St. Joe’s Interior lands.
Kerrisdale Capital also issued a negative report on a company that deals in development stage biopharmaceutical products called Proteostasis Therapeutics. The company’s lead drug for the treatment of cystic fibrosis, PTI-428 will fail in phase 3 trails according to Kerrisdale although its stock price has increased following flawed stage 2 outcome that had a bad result but was hidden.